June 1, 2023
Apogenix’ new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model
March 27, 2023
Apogenix’ Partner CANbridge Announces 67 % Five-Year Overall Survival Rate Compared to 8.2 % in Institutional Database With Asunercept Plus SOC in Newly Diagnosed Glioblastoma Multiforme Patients
...